Delivery of negatively charged liposomes into the atheromas of Watanabe heritable hyperlipidemic rabbits

Vascular Medicine

Volumn 15, Issue 4, 2010, Pages 307-313

  Walton, Brian L ^a   Leja, Monika ^b   Vickers, Kasey C ^c   Estevez Fernandez, Monica ^d   Sanguino, Angela ^d   Wang, Elizabeth ^e   Clubb Jr , Fred J ^e   Morrisett, Joel ^c   Lopez Berestein, Gabriel ^d  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e TEXAS HEART INSTITUTE   (United States)

Author keywords

Atherosclerosis; Lipoprotein associated phospholipase A2; Liposomes

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; LIPOSOME; RHODAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROMA; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TARGETING; ELECTRON MICROSCOPY; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RABBIT; THORACIC AORTA; TRANSMISSION ELECTRON MICROSCOPY;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; AORTA, THORACIC; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FREEZE FRACTURING; GOLD; HYPERLIPIDEMIAS; INJECTIONS, INTRA-ARTERIAL; LIPOSOMES; METAL NANOPARTICLES; MICROSCOPY, ELECTRON; PLAQUE, ATHEROSCLEROTIC; RABBITS; RHODAMINES;

EID: 77955908538     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X10374118     Document Type: Article

References (36)

1. Yusuf S., Reddy S., Ounpuu S., Anand S. Global burden of car diovascular diseases: Part I: general considerations, the epide miologic transition, risk factors, and impact of urbanization. Circulation 2001 ; 104: 2746-2753.
2. Jefferson BK, Topol EJ Molecular mechanisms of myocar dial infarction. Curr Probl Cardiol 2005 ; 30: 333-374.
3. Fuster V., Moreno PR, Fayad ZA, et al. Atherothrombosis and high risk plaque: Part I: evolving concepts. J Am Coll Cardiol 2005 ; 46: 937-954.
4. Granada JF, Kaluza GL, Raizner AE, Moreno PR Vulnerable plaque paradigm: prediction of future clinical events based on a morphological definition. Catheter Cardiovasc Interv 2004 ; 62: 364-374.
5. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999 ; 340: 115-126.
6. Quinn MT, Parthasarathy S., Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A 1987 ; 84: 2995-2998.
7. Stocker R., Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004 ; 84: 1381-1478.
8. Ambrose JA, Tannenbaum MA, Alexopoulos D., et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988 ; 12: 56-62.
9. Moreno PR, Purushothaman KR, Fuster V., O'Connor WN Intimomedial interface damage and adventitial inflammation is increased beneath disrupted atherosclerosis in the aorta: implications for plaque vulnerability. Circulation 2002 ; 105: 2504-2511.
10. Libby P. Inflammation in atherosclerosis. Nature 2002 ; 420: 868-874.
11. Huang SL, Hamilton AJ, Nagaraj A., et al. Improving ultrasound reflectivity and stability of echogenic liposomal dispersions for use as targeted ultrasound contrast agents. J Pharm Sci 2001 ; 90: 1917-1926.
12. Wickline SA, Lanza GM Nanotechnology for molecu lar imaging and targeted therapy. Circulation 2003 ; 107: 1092-1095.
13. French BA, Mazur W., Ali NM, et al. Percutaneous translu minal in vivo gene transfer by recombinant adenovirus in normal porcine coronary arteries, atherosclerotic arteries, and two models of coronary restenosis. Circulation 1994 ; 90: 2402-2413.
14. Gregoriadis G. The carrier potential of liposomes in biology and medicine (first of two parts). N Engl J Med 1976 ; 295: 704-710.
15. Gregoriadis G. The carrier potential of liposomes in biology and medicine (second of two parts). N Engl J Med 1976 ; 295: 765-770.
16. Lopez Berestein G. Liposomes as carriers of antimicrobial agents. Antimicrob Agents Chemother 1987 ; 31: 675-678.
17. Lopez Berestein G. Liposomes in infectious diseases: pres ent and future. Curr Clin Top Infect Dis 1989 ; 10: 241-253.
18. Lopez Berestein G., Rosenblum MG, Mehta R. Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Deliv 1984 ; 1: 199-205.
19. Mazur W., Ali NM, Grinstead WC, et al. Lipofectin mediated versus adenovirus mediated gene transfer in vitro and in vivo: comparison of canine and porcine model systems. Coron Artery Dis 1994 ; 5: 779-786.
20. Ng AW, Wasan KM, Lopez Berestein G. Development of liposomal polyene antibiotics: an historical perspective. J Pharm Pharm Sci 2003 ; 6: 67-83.
21. Siwak DR, Tari AM, Lopez Berestein G. The potential of drug carrying immunoliposomes as anticancer agents. Commentary re: J. W. Park et al., Anti HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin Cancer Res., 8: 1172-1181, 2002. Clin Cancer Res 2002 ; 8: 955-956.
22. Tari AM, Tucker SD, Deisseroth A., Lopez Berestein G. Liposomal delivery of methylphosphonate antisense oligo deoxynucleotides in chronic myelogenous leukemia. Blood 1994 ; 84: 601-607.
23. Tiukinhoy SD, Khan AA, Huang S., et al. Novel echogenic drug immunoliposomes for drug delivery. Invest Radiol 2004 ; 39: 104-110.
24. Demos SM, Onyuksel H., Gilbert J., et al. In vitro target ing of antibody conjugated echogenic liposomes for site specific ultrasonic image enhancement. J Pharm Sci 1997 ; 86: 167-171.
25. Hamilton AJ, Huang SL, Warnick D., et al. Intravascular ultrasound molecular imaging of atheroma components in vivo. J Am Coll Cardiol 2004 ; 43: 453-460.
26. Bangham AD Lipid bilayers and biomembranes. Annu Rev Biochem 1972 ; 41: 753-776.
27. Tari AM, Fuller N., Boni LT, et al. Interactions of liposome bilayers composed of 1,2 diacyl 3 succinylglycerol with protons and divalent cations. Biochim Biophys Acta 1994 ; 1192: 253-262.
28. Naghavi M., Libby P., Falk E., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003 ; 108: 1664-1672.
29. Carr S., Farb A., Pearce WH, et al. Atherosclerotic plaque rupture in symptomatic carotid artery stenosis. J Vasc Surg 1996 ; 23: 755-765 ; discussion 765-766.
30. Little WC, Constantinescu M., Applegate RJ, et al. Can coro nary angiography predict the site of a subsequent myocardial infarction in patients with mild to moderate coronary artery disease? Circulation 1988 ; 78: 1157-1166.
31. Hakkinen T., Luoma JS, Hiltunen MO, et al. Lipoprotein associated phospholipase A(2), platelet activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999 ; 19: 2909-2917.
32. Macphee C., Benson GM, Shi Y., Zalewski A. Lipoprotein associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target. Expert Opin Investig Drugs 2005 ; 14: 671-679.
33. Macphee CH, Nelson JJ, Zalewski A. Lipoprotein associated phospholipase A2 as a target of therapy. Curr Opin Lipidol 2005 ; 16: 442-446.
34. Filion MC, Phillips NC Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta 1997 ; 1329: 345-356.
35. Lonez C., Vandenbranden M., Elouahabi A., Ruysschaert JM Cationic lipid/DNA complexes induce TNF-α secretion in splenic macrophages. Eur J Pharm Biopharm 2008 ; 69: 817-823.
36. Gabizon A., Papahadjopoulos D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta 1992 ; 1103: 94-100.